Abstract: The system can be for the management of access authorization using an immutable ledger comprising and can include a server having a computer readable medium in communications with an immutable ledger. A set of computer readable instructions can be included in the server and can be configured for: receiving a set of data, encrypting the set of data with a data-encryption-key and storing the encrypted data on the immutable ledger, creating a key tree having a node associated with a user, creating a key-encryption-key associated with the node and the user, and, distributing the key-encryption-key to the user wherein the key-encryption-key is configured to decrypt the data-encryption-key thereby providing access to the data for the user.

Abstract: Joints, such as adhesive and welded thermoplastic joints, comprising embedded and/or surface mounted components of a sensor system are provided. The embedded and/or surface mounted component can be an optical fiber. Strain and/or stress can be monitored in the joint in a spatially resolved manner periodically or continuously, for example, to warn of potential failure of the joint or estimate residual/remaining life of a bonded component. The stress and/or strain information can also be used to improve the design of the joint. Methods and systems for monitoring stress and/or strain in a joint, and methods of preparing the joints are provided, as well.

Abstract: A multivalent immunogenic composition is provided, including one or more recombinant proteins selected from the group consisting of a recombinant attenuated Staphylococcus pseudintermedius Protein A (SEQ ID NO:2), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin S (SEQ ID NO:4), a recombinant attenuated Staphylococcus pseudintermedius Nucleotidase adenosine synthase protein (AdsA) (SEQ ID NO:6), a recombinant attenuated Staphylococcus pseudintermedius coagulase (SEQ ID NO:8), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin F (SEQ ID NO: 10), and a recombinant attenuated Staphylococcus pseudintermedius exotoxin 15 (SEQ ID NO: 12). Synthetic genes expressing the attenuated recombinant proteins and optimized for expression in E. coli are provided. Vaccines and therapeutic compositions comprising the one or more recombinant proteins are provided.

Abstract: A method for enhancing plant growth by pre-soaking a seed or plant material to be germinated with a drop of an iron oxide nanoparticle solution or dispersion is described. Pre-soaking the seed or other plant material with the nanoparticle solution or dispersion can, among other things, increase the growth rate, life span, fruit production of the plants grown from the pre-soaked seed or other material. Also described are the iron oxide nanoparticles themselves, and methods of preparing the iron oxide nanoparticles. The size, morphology, and surface charge of the iron oxide nanoparticles can be influenced by polymeric organic ligands used in the preparation of the nanoparticles.

Abstract: The present disclosure provides novel ATX inhibitors, and pharmaceutical compositions comprising said inhibitors, as well as methods of treatment comprising administration of said inhibitors.

Abstract: Continuous positive airway pressure (CPAP) devices and systems including patient-specific mandibular and nasal component, configured to deliver pressurized air to nasal and oral passageways of a subject. Mask-less and strap-less CPAP devices designed to provide dual delivery of continuous pressurized air to a mouth and nose of a subject. Methods of treating and ameliorating sleep apnea, hypopnea syndrome, and obstructive sleep apnea.

Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.

Abstract: Processes for preparing neutral liposomes include adding a hydrophobic solution of liposome lipid bilayer precursors and a nucleic acid condenser to an aqueous composition of a nucleic acid condenser and a biologically active ingredient and then, isolating the liposomes. The liposomes are formed from noncationic lipids and encapsulate the biologically active ingredient as a core composition and entrap some of the biologically active ingredient on the exterior surface of the liposome. The liposomes have the nucleic acid condensers and/or cell penetrating peptides attached to the exterior surface of the lipid bilayer. One or more divalent cations are present in the solution with the liposome and remain in solution once the liposomes form.

Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.

Abstract: This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject.

Abstract: Systems and methods for detecting a tampering and identifying a location of a digital recording are provided. A frequency sequence and a phase angle sequence may be extracted from the digital recording. A portion of the frequency sequence may be matched to one of a plurality of reference frequency sequences, and a portion of the phase angle sequence may be matched to one of a plurality of reference phase angle sequences. Tampering of the digital recording may be detected when the frequency and phase sequences differ from the matched reference sequences. Moreover, a noise sequence may be extracted from the extracted frequency sequence. A location of the digital recording may be identified by matching the noise sequence to one of a plurality of noise sequences of the plurality of reference frequency sequences.

Abstract: Mixed halide scintillation materials of the general formula AB(1?y)MyX?wX?(3?w), where 0?y?1, 0.05?w?1, A may be an alkali metal, B may be an alkali earth metal, and X? and X? may be two different halogen atoms, and of the general formula A(1?y)BMyX?wX?(3?w), where 0?y?1, 0.05?w?1, A maybe an alkali metal, B may be an alkali earth metal, and X? and X? are two different halogen atoms. The scintillation materials of formula (1) include a divalent external activator, M, such as Eu2+ or Yb2+. The scintillation materials of formula (2) include a monovalent external activator, M, such as Tl+, Na+ and In+.

Abstract: This invention is directed to selective androgen receptor degrader (SARD) compounds including heterocyclic rings and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: A solid multiphase polymer blend material comprising: (i) a polyphenolic substance having a molecular weight of at least 500 g/mol; and (ii) a polyester having a molecular weight of at least 500 g/mol; wherein at least a portion of the polyphenolic substance is covalently bonded directly or through a linking moiety to the polyester. Methods for producing the blend material are also described, e.g., homogeneously melt blending a mixture comprising components (i) and (ii) under conditions resulting in covalent attachment of at least a portion of the polyphenolic substance directly or through a linking moiety to the polyester. Methods for producing objects made of the blend material by melt extrusion are also described.

Abstract: The present disclosure is directed to methods of improving mycorrhization in a plant or plant cell. Another aspect of this disclosure is directed to a genetically modified plant or plant cell with improved mycorrhization.

Abstract: An electrochemical cell includes an air electrode in flow communication with a storage tank containing an aqueous solution of hydrogen peroxide, a lithium electrode, a catalyst layer in contact with the air electrode or a gas diffusion layer associated with the air electrode, and a separator layer in contact with the lithium electrode and catalyst layer. The catalyst layer includes a catalyst for two electron reversible oxygen reduction. The catalyst comprises gold, and a cobalt coordination complex or polymer thereof. The cobalt coordination complex comprises a cobalt ion chelated by a tetradentate organic chelating ligand.

Abstract: This invention is directed to selective androgen receptor degrader (SARD) compounds pharmaceutical compositions and uses thereof in treating early prostate cancer, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: A method of producing a cellular structure via an additive manufacturing technique includes the steps of: providing a feedstock material to an additive manufacturing printer device; dispensing the feedstock material from the printer device; and controlling the dispensing of the feedstock material to form at least one layer of the cellular structure according to a first predetermined gradient. In some aspects, the cellular structure comprises an array of cells surrounded, respectively, by walls, and arranged to create a non-uniform relative density and/or cell geometry across a width and/or a height of the cellular structure. An article of manufacture produced by such methods includes a cellular structure configured to produce a controlled collapse with selectable dynamic stiffness characteristics by altering the distribution and geometry of cells within the cellular structure, while being able to maintain a substantially similar static stiffness characteristic.

Abstract: A system includes a controller that is configured to generate a plurality of switch control signals; a plurality of electrical circuit elements, the plurality of electrical circuit elements being characterized by a plurality of impedances, respectively; a plurality of voltage sources; and a plurality of switches that are programmable to couple the plurality of electrical circuit elements to the plurality of voltage sources responsive to the plurality of switch control signals.